Results 61 to 70 of about 1,547 (116)

Supplementary Material for: Efficacy, Safety and Quality of Life of Pegcetacoplan in Japanese Patients With Paroxysmal Nocturnal Hemoglobinuria Treated Within the Phase 3 PEGASUS Trial

Introduction: Pegcetacoplan, the first approved proximal complement C3 inhibitor, showed superiority to eculizumab in improving hemoglobin levels and clinical outcomes in the phase 3 PEGASUS study in patients with paroxysmal nocturnal hemoglobinuria (PNH)
Usuki K. (18351372), Nakazawa H. (18351366), Uchida T. (10508516), deLatour R.P. (18351378), Panse J. (18351384), Röth A. (18351381), Tamura S. (18351369), Nishimori H. (18351363), Szamosi J. (18351375)   +8 more
core   +1 more source

The effect of syringe design and cannula dimensions on time-force curve in intravitreal injection across different drug viscosities: area under the curve and peak injection force

International Journal of Retina and Vitreous
Background New intravitreal medications can offer longer treatment duration by using higher drug concentrations, which, in turn, increase viscosity. There is also a trend toward having smaller-gauge cannulas, which require a higher injection force. While
Bryan Calder Ackermann, Niklas Junker, Maximilian Friedrich, Øystein Kalsnes Jørstad, Morten C. Moe, Victor Aristide Augustin, Gerd Uwe Auffarth, Maximilian Hammer   +7 more
doaj   +1 more source

Treatment Patterns and Healthcare Resource Utilization of Patients With Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Claims Data Analysis

Clinical and Applied Thrombosis/Hemostasis
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder commonly treated with complement inhibitors such as eculizumab, ravulizumab, and pegcetacoplan.
Denise Clayton PhD, Jason Shafrin PhD, Glorian Yen PhD, MPH, Soyon Lee PharmD, Lincy Geevarghese MD, Yulin Shi MS, Luyang He MS, Ying Shen MS, Anem Waheed MD, MPH   +8 more
doaj   +1 more source

Supplementary materials: The cost–effectiveness of pegcetacoplan in complement treatment-na¨ıve adults with paroxysmal nocturnal hemoglobinuria in the USA

These are peer-reviewed supplementary materials for the article 'The cost–effectiveness of pegcetacoplan in complement treatment-naive adults with paroxysmal nocturnal hemoglobinuria in the USA' published in the Journal of Comparative Effectiveness ...
Jesse Fishman (818188), Koo Wilson (5548376), Aleksandra Drzewiecka (13280638), Michal Pochopien (6192851), David Dingli (45713)   +4 more
core   +1 more source

A Beacon of Hope: Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN. [PDF]

Clin J Am Soc Nephrol
Owoyemi I, Moxey-Mims MM.
europepmc   +1 more source

Intraocular inflammation and presumed retinal vasculitis following initial pegcetacoplan intravitreal injection. [PDF]

Digit J Ophthalmol
Seela JR, Zubair T, Vagaggini T, Williams DF.   +3 more
europepmc   +1 more source

PB2054: EXPOSURE-RESPONSE ANALYSES OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

HemaSphere, 2023
Haili Ping, Brandon Smith, Sven Adriaens, Ryan Crass, Sunny Chapel, Temitayo Ajayi   +5 more
doaj   +1 more source

Pegcetacoplan as a targeted C3 inhibitor in C3 glomerulopathy and immune-complex MPGN. [PDF]

Ann Med Surg (Lond)
Habib E, Hajj F.
europepmc   +1 more source

Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study

INTRODUCTION: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening disease characterized by complement-mediated hemolysis and thrombosis. Pegcetacoplan, the first targeted complement component 3 (C3) PNH therapy, was safe and efficacious
Panse, Jens Peter, Bogdanovic, A, Yeh, M, Maciejewski, JP, Horneff, Regina, Mulherin, Brian, Panse, Jens, Röth, Alexander, Patriquin, CJ, Selvaratnam, V, Tan, Lisa, Horneff, R, Griffin, Morag, Peffault de Latour, R, Tan, L, Maciejewski, Jaroslaw P., Bogdanovic, Andrija, Yeh, Michael, Patriquin, Christopher J., Al-Adhami, Mohammed, Griffin, M, Kelly, RJ, Peffault de Latour, Régis, Röth, A, Al-Adhami, M, Szer, Jeffrey, Kelly, Richard J., Mulherin, B, Panse, J, Szer, J, Selvaratnam, Veena   +30 more
core   +1 more source

Predictive Value of Perilesional Fundus Autofluorescence Patterns and OCT-Based Ellipsoid Zone/Retinal Pigment Epithelium Loss Ratios in Geographic Atrophy Growth Rates. [PDF]

Ophthalmol Sci
Mai J, Reiter GS, Riedl S, Vogl WD, Sadeghipour A, McKeown A, Foos E, Schwartz R, Sacu S, Bogunovic H, Schmidt-Erfurth U.   +10 more
europepmc   +1 more source